Meclizine Hydrochloride description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

Meclizine Hydrochloride

AvKARE, Inc.




FULL PRESCRIBING INFORMATION

Chemically, meclizine hydrochloride is 1-(p-chloro-α-phenylbenzyl)-4-(m-methylbenzyl) piperazine dihydrochloride monohydrate.

Meclizine Hydrochloride

Inactive ingredients include: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium starch glycolate and talc. The 12.5 mg tablets also contain FD&C Blue # 1 Aluminum Lake.  The 25 mg tablet also contains D&C Yellow # 10 Aluminum Lake.

Meclizine Hydrochloride is an antihistamine which shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.

Management of nausea and vomiting, and dizziness associated with motion sickness.

Meclizine HCl is contraindicated in individuals who have shown a previous hypersensitivity to it.

Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.

Patients should avoid alcoholic beverages while taking this drug.

Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland.

Pediatric Use

Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended in children under 12 years of age.

Pregnancy Use

Pregnancy Category B. Reproduction studies in rats have shown cleft palates at 25 to 50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that meclizine increases the risk of abnormalities when administered during pregnancy. Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine, or any other medication, should be used during pregnancy only if clearly necessary.

Drowsiness, dry mouth and, on rare occasions, blurred vision have been reported.

Motion Sickness

The initial dose of 25 to 50 mg of Meclizine Hydrochloride Tablets should be taken one hour prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.

Meclizine Hydrochloride Tablets, USP 12.5 mg are light blue colored, oval shaped tablets with “AN 441” debossed on one side and plain on the other side.

They are available as follows:

Bottles of 90: NDC 42291-608-90
Bottles of 1000: NDC 42291-608-10

Meclizine Hydrochloride Tablets, USP 25 mg are light yellow colored, oval shaped tablets with “AN 442” debossed on one side and plain on the other side.

They are available as follows:

Bottles of 90: NDC 42291-609-90
Bottles of 1000: NDC 42291-609-10

Meclizine Hydrochloride Tablets, USP 50 mg are white, oval shaped, partially bisected tablets with “AN 444” debossed on one side and plain on the other side.

They are available as follows:

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Dispense in a tight, light-resistant container.

Manufactured for:
AvKARE, Inc.
Pulaski, TN 38478

Mfg. Rev. 12/10
AV Rev. 04/13 (P)

AvKARE
NDC 42291-608-10

Meclizine Hydrochloride Tablets, USP

12.5 mg
1000 Tablets        Rx Only

Each tablets contains:
Meclizine HCl..................12.5mg

Store at 20o to 25oC (68o to 77oF) [See USP Controlled Room Temperature.]

Dispense in tight, light-resistant containers as defined in the USP.

DOSAGE AND USE: See accompanying prescribing information.

MOTION SICKNESS: 25mg to 50mg daily.

Manufactured for:
AvKARE, Inc.
Pulaski, TN 38478

Mfg. Rev. 02/11       AV Rev. 04/13 (P)

N3   42291 60810   8

AvKARE
NDC 42291-609-10

Meclizine Hydrochloride Tablets, USP

25 mg
1000 Tablets        Rx Only

Each tablets contains:
Meclizine HCl..................25mg

Store at 20o to 25oC (68o to 77oF) [See USP Controlled Room Temperature.]

Dispense in tight, light-resistant containers as defined in the USP.

DOSAGE AND USE: See accompanying prescribing information.

MOTION SICKNESS: 25mg to 50mg daily.

Manufactured for:
AvKARE, Inc.
Pulaski, TN 38478

Mfg. Rev. 02/11       AV Rev. 04/13 (P)

N3   42291 60910   5

Meclizine Hydrochloride

Meclizine TABLET

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:42291-608(NDC:65162-441)
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
MECLIZINE HYDROCHLORIDE MECLIZINE 12.5 mg

Inactive Ingredients

Ingredient Name Strength
SILICON DIOXIDE
lactose monohydrate
MAGNESIUM STEARATE
cellulose, microcrystalline
SODIUM STARCH GLYCOLATE TYPE A POTATO
talc
FD&C BLUE NO. 1

Product Characteristics

Color Size Imprint Code Shape
BLUE (Light) 10 mm AN;441 OVAL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:42291-608-90 90 in 1 BOTTLE
2 NDC:42291-608-10 1000 in 1 BOTTLE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA201451 2012-05-04


Meclizine Hydrochloride

Meclizine Hydrochloride TABLET

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:42291-609(NDC:65162-442)
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
MECLIZINE HYDROCHLORIDE MECLIZINE 25 mg

Inactive Ingredients

Ingredient Name Strength
SILICON DIOXIDE
lactose monohydrate
MAGNESIUM STEARATE
cellulose, microcrystalline
SODIUM STARCH GLYCOLATE TYPE A POTATO
talc
D&C YELLOW NO. 10

Product Characteristics

Color Size Imprint Code Shape
YELLOW (Light) 13 mm AN;442 OVAL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:42291-609-90 90 in 1 BOTTLE
2 NDC:42291-609-10 1000 in 1 BOTTLE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA201451 2012-05-04


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.